March 11, 2025 09:50 AM EDTUpdated 01:21 PM

Corrected: Merck opens billion-dollar US facility to make Gardasil

Ayisha Sharma

News Reporter

Merck has opened a new manufacturing plant in Durham, NC which will make HPV vaccines, including its quadrivalent vaccine Gardasil and nine-valent vaccine Gardasil 9 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Corrected: Merck opens billion-dollar US facility to make Gardasil

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Arvinas, Pfizer’s PROTAC data fall short of hype in breast cancer

FDA’s medical review departments remain untouched (for now) by Musk’s cuts

Bristol Myers buys out cell therapy partner 2seventy bio

Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug

Merck scores a win in Gardasil cases after judge says plaintiffs’ evidence ‘falls far short’

Obesity drug development—still room to grow

Cor­rect­ed: Mer­ck opens bil­lion-dol­lar US fa­cil­i­ty to make Gar­dasil

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Arv­inas, Pfiz­er’s PRO­TAC da­ta fall short of hype in breast can­cer

FDA’s med­ical re­view de­part­ments re­main un­touched (for now) by Musk’s cuts

Bris­tol My­ers buys out cell ther­a­py part­ner 2sev­en­ty bio

Gilead plans to skip from Phase 1 to Phase 3 with once-year­ly HIV pre­ven­tion drug

Mer­ck scores a win in Gar­dasil cas­es af­ter judge says plain­tiffs’ ev­i­dence ‘falls far short’

Obe­si­ty drug de­vel­op­ment—still room to grow

Corrected: Merck opens billion-dollar US facility to make Gardasil

Arvinas, Pfizer’s PROTAC data fall short of hype in breast cancer

FDA’s medical review departments remain untouched (for now) by Musk’s cuts

Bristol Myers buys out cell therapy partner 2seventy bio

Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug

Merck scores a win in Gardasil cases after judge says plaintiffs’ evidence ‘falls far short’

Obesity drug development—still room to grow